Key Insights

Highlights

Success Rate

100% trial completion (above average)

Treatment Research

2 treatments under study, led by Topical Afx5931

Research Leaders

5 sponsors active, led by Regionshospital Nordjylland

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 30/100

Termination Rate

0.0%

0 terminated out of 3 trials

Success Rate

100.0%

+13.4% vs benchmark

Late-Stage Pipeline

33%

1 trials in Phase 3/4

Results Transparency

33%

1 of 3 completed with results

Key Signals

1 with results100% success

Data Visualizations

Phase Distribution

2Total
Not Applicable (1)
Phase 4 (1)

Trial Status

Completed3

Trial Success Rate

100.0%

Benchmark: 86.6%

Based on 3 completed trials

Clinical Trials (3)

Showing 3 of 3 trials
NCT03703895Phase 4CompletedPrimary

A Study for a Topical Medication Versus Placebo in Patients With Hand Dermatitis

NCT04375410Completed

Consequences of Intensified Handwash and Hand Disinfection Among Children During the COVID19 Pandemic

NCT01950494Not ApplicableCompletedPrimary

FiteBac Hand Sanitizer in the Management of Hand Dermatitis in Adults

Showing all 3 trials

Research Network

Common Treatments

  • Topical Afx59311
  • Fitebac Hand Sanitizer1

Active Sponsors

  • Regionshospital Nordjylland1
  • National Jewish Health1
  • Afecta Pharmaceuticals1
  • Aalborg University Hospital1
  • The Center for Clinical and Cosmetic Research1

Top Investigators

Related Conditions

  • Covid191
  • Hand Eczema1

Activity Timeline